South Korea · Delayed Price · Currency is KRW Medy-Tox Statistics
Total Valuation
Medy-Tox has a market cap or net worth of KRW 856.37 billion. The enterprise value is 876.61 billion.
| Market Cap | 856.37B |
| Enterprise Value | 876.61B |
Important Dates
The last earnings date was Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Medy-Tox has 7.02 million shares outstanding. The number of shares has decreased by -3.59% in one year.
| Current Share Class | 7.02M |
| Shares Outstanding | 7.02M |
| Shares Change (YoY) | -3.59% |
| Shares Change (QoQ) | +9.37% |
| Owned by Insiders (%) | 19.28% |
| Owned by Institutions (%) | 11.41% |
| Float | 5.23M |
Valuation Ratios
The trailing PE ratio is 35.90 and the forward PE ratio is 19.83.
| PE Ratio | 35.90 |
| Forward PE | 19.83 |
| PS Ratio | 3.54 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 1.90 |
| P/FCF Ratio | 15.96 |
| P/OCF Ratio | 13.97 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.08, with an EV/FCF ratio of 16.33.
| EV / Earnings | 40.13 |
| EV / Sales | 3.63 |
| EV / EBITDA | 18.08 |
| EV / EBIT | 30.96 |
| EV / FCF | 16.33 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.79 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 1.83 |
| Debt / FCF | 1.42 |
| Interest Coverage | 12.53 |
Financial Efficiency
Return on equity (ROE) is 4.38% and return on invested capital (ROIC) is 2.41%.
| Return on Equity (ROE) | 4.38% |
| Return on Assets (ROA) | 2.23% |
| Return on Invested Capital (ROIC) | 2.41% |
| Return on Capital Employed (ROCE) | 4.40% |
| Revenue Per Employee | 342.97M |
| Profits Per Employee | 30.98M |
| Employee Count | 705 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.84 |
Taxes
In the past 12 months, Medy-Tox has paid 112.04 million in taxes.
| Income Tax | 112.04M |
| Effective Tax Rate | 0.53% |
Stock Price Statistics
The stock price has decreased by -5.49% in the last 52 weeks. The beta is 0.16, so Medy-Tox's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -5.49% |
| 50-Day Moving Average | 121,862.00 |
| 200-Day Moving Average | 140,296.50 |
| Relative Strength Index (RSI) | 53.59 |
| Average Volume (20 Days) | 34,650 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medy-Tox had revenue of KRW 241.80 billion and earned 21.84 billion in profits. Earnings per share was 3,398.79.
| Revenue | 241.80B |
| Gross Profit | 139.81B |
| Operating Income | 21.64B |
| Pretax Income | 21.26B |
| Net Income | 21.84B |
| EBITDA | 41.82B |
| EBIT | 21.64B |
| Earnings Per Share (EPS) | 3,398.79 |
Balance Sheet
The company has 59.33 billion in cash and 76.39 billion in debt, giving a net cash position of -17.06 billion or -2,430.06 per share.
| Cash & Cash Equivalents | 59.33B |
| Total Debt | 76.39B |
| Net Cash | -17.06B |
| Net Cash Per Share | -2,430.06 |
| Equity (Book Value) | 467.65B |
| Book Value Per Share | 66,165.36 |
| Working Capital | 75.11B |
Cash Flow
In the last 12 months, operating cash flow was 61.30 billion and capital expenditures -7.63 billion, giving a free cash flow of 53.67 billion.
| Operating Cash Flow | 61.30B |
| Capital Expenditures | -7.63B |
| Free Cash Flow | 53.67B |
| FCF Per Share | 7,645.63 |
Margins
Gross margin is 57.82%, with operating and profit margins of 8.95% and 9.44%.
| Gross Margin | 57.82% |
| Operating Margin | 8.95% |
| Pretax Margin | 8.79% |
| Profit Margin | 9.44% |
| EBITDA Margin | 17.29% |
| EBIT Margin | 8.95% |
| FCF Margin | 22.20% |
Dividends & Yields
This stock pays an annual dividend of 1,100.00, which amounts to a dividend yield of 0.90%.
| Dividend Per Share | 1,100.00 |
| Dividend Yield | 0.90% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 36.92% |
| Buyback Yield | 3.59% |
| Shareholder Yield | 4.49% |
| Earnings Yield | 2.55% |
| FCF Yield | 6.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Medy-Tox has an Altman Z-Score of 6.68 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.68 |
| Piotroski F-Score | 6 |